EMAIL THIS PAGE TO A FRIEND

International journal of pharmaceutics

Study of sodium hyaluronate-based intranasal formulations containing micro- or nanosized meloxicam particles.


PMID 26142244

Abstract

This article reports on the micro- and nanonization of meloxicam (MEL) with the aim of developing pre-dispersions as intermediates for the design of intranasal formulations. As a new approach, combined wet milling technology was developed in order to reduce the particle size of the MEL. Different milling times resulted in micro- or nanosized MEL in the pre-dispersions with polyvinyl alcohol as stabilizer agent, which were directly used for preparing intranasal liquid formulations with the addition of sodium hyaluronate as mucoadhesive agent. Reduction of the MEL particle size into the nano range led to increased saturation solubility and dissolution velocities, and increased adhesiveness to surfaces as compared with microsized MEL particles. A linear correlation was demonstrated between the specific surface area of MEL and the AUC. The in vitro and in vivo studies indicated that the longer residence time and the uniform distribution of nano MEL spray throughout an artificial membrane and the nasal mucosa resulted in better diffusion and a higher AUC. Nanosized MEL may be suggested for the development of an innovative dosage form with a different dose of the drug, as a possible administration route for pain management.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

P5654
Piroxicam, ≥98% (TLC)
C15H13N3O4S
P0847
Piroxicam, meets USP testing specifications
C15H13N3O4S